Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Am J Hematol 2018 Jun 8. Epub 2018 Jun 8.

Department of Hematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.

Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pre-treated before anti-PD-1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti-PD1 therapy were progressive disease (PD) (n=24) and partial response (PR) (n=6). For the 24 PD patients, median anti-PD-1 related PFS was 7.5 months (95%CI, 5.7-11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti-PD-1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow-up of 12.1 months (7-14.7), the median PFS following the initiation of CT was 11 months (95%CI, 6.3; not reached) and the median of overall survival was not reached. These observations in highly pre-treated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT. This article is protected by copyright. All rights reserved.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25154DOI Listing
June 2018
20 Reads

Publication Analysis

Top Keywords

anti-pd-1 therapy
16
anti-pd-1
8
patients
8
relapsed refractory
8
hodgkin lymphoma
8
highly pre-treated
8
months 95%ci
8
response
6
therapy
5
median
5
treated twelve
4
patients highly
4
pre-treated anti-pd-1
4
patients treated
4
anti-pd-1 70%
4
asct 93%
4
93% unsatisfactory
4
median pfs
4
proceeded allogeneic
4
received asct
4

Altmetric Statistics

References

(Supplied by CrossRef)

Similar Publications